Standardization of Cell Culture Conditions and Routine Genomic Screening under a Quality Management System Leads to Reduced Genomic Instability in hPSCs

dc.contributor.authorMolina Ruiz, Francisco Jose
dc.contributor.authorIntrona, Clelia
dc.contributor.authorBombau, Georgina
dc.contributor.authorGalofré, Mireia
dc.contributor.authorCanals i Coll, Josep M.
dc.date.accessioned2023-03-20T15:57:13Z
dc.date.available2023-03-20T15:57:13Z
dc.date.issued2022-05-21
dc.date.updated2023-03-20T15:57:13Z
dc.description.abstractHuman pluripotent stem cells (hPSCs) have generated unprecedented interest in the scientific community, given their potential applications in regenerative medicine, disease modeling, toxicology and drug screening. However, hPSCs are prone to acquire genomic alterations in vitro, mainly due to suboptimal culture conditions and inappropriate routines to monitor genome integrity. This poses a challenge to both the safety of clinical applications and the reliability of basic and translational hPSC research. In this study, we aim to investigate if the implementation of a Quality Management System (QMS) such as ISO9001:2015 to ensure reproducible and standardized cell culture conditions and genomic screening strategies can decrease the prevalence of genomic alterations affecting hPSCs used for research applications. To this aim, we performed a retrospective analysis of G-banding karyotype and Comparative Genomic Hybridization array (aCGH) data generated by our group over a 5-year span of different hESC and hiPSC cultures. This work demonstrates that application of a QMS to standardize cell culture conditions and genomic monitoring routines leads to a striking improvement of genomic stability in hPSCs cultured in vitro, as evidenced by a reduced probability of potentially pathogenic chromosomal aberrations and subchromosomal genomic alterations. These results support the need to implement QMS in academic laboratories performing hPSC research.
dc.format.extent25 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec732685
dc.identifier.issn2073-4409
dc.identifier.pmid35805069
dc.identifier.urihttps://hdl.handle.net/2445/195640
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cells11131984
dc.relation.ispartofCells, 2022, vol. 11, num. 13, p. 1984
dc.relation.urihttps://doi.org/10.3390/cells11131984
dc.rightscc-by (c) Molina Ruíz, Francisco J. et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Biomedicina)
dc.subject.classificationNorma ISO 9001
dc.subject.classificationTeràpia cel·lular
dc.subject.classificationGenòmica
dc.subject.classificationCèl·lules mare
dc.subject.classificationCariotips
dc.subject.classificationCultius cel·lulars humans
dc.subject.otherISO 9001 Standard
dc.subject.otherCellular therapy
dc.subject.otherGenomics
dc.subject.otherStem cells
dc.subject.otherKaryotypes
dc.subject.otherHuman cell culture
dc.titleStandardization of Cell Culture Conditions and Routine Genomic Screening under a Quality Management System Leads to Reduced Genomic Instability in hPSCs
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
732685.pdf
Mida:
2.47 MB
Format:
Adobe Portable Document Format